| Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report P Malfertheiner, F Megraud, C O’Morain, F Bazzoli, E El-Omar, D Graham, ... Gut 56 (6), 772-781, 2007 | 5607* | 2007 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2192 | 2013 |
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised … DEMETRI G LANCET 381, 295-302, 2013 | 1571 | 2013 |
| 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial A Halliday, M Harrison, E Hayter, X Kong, A Mansfield, J Marro, H Pan, ... The Lancet 376 (9746), 1074-1084, 2010 | 1134 | 2010 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67, 2018 | 936 | 2018 |
| Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized … GD Demetri, M Von Mehren, RL Jones, ML Hensley, SM Schuetze, ... Journal of Clinical Oncology 34 (8), 786-793, 2016 | 884 | 2016 |
| Raman techniques: fundamentals and frontiers RR Jones, DC Hooper, L Zhang, D Wolverson, VK Valev Nanoscale research letters 14, 1-34, 2019 | 758 | 2019 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ... Annals of Oncology 32 (11), 1348-1365, 2021 | 691 | 2021 |
| Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial WD Tap, RL Jones, BA Van Tine, B Chmielowski, AD Elias, D Adkins, ... The Lancet 388 (10043), 488-497, 2016 | 685 | 2016 |
| Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv68-iv78, 2018 | 630 | 2018 |
| Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study COVIDSurg Collaborative Anaesthesia 76 (6), 748-758, 2021 | 598* | 2021 |
| Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 593 | 2018 |
| Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study F Grosso, RL Jones, GD Demetri, IR Judson, JY Blay, A Le Cesne, ... The lancet oncology 8 (7), 595-602, 2007 | 556 | 2007 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 458 | 2020 |
| Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients DSP Tan, C Marchió, RL Jones, K Savage, IE Smith, M Dowsett, ... Breast cancer research and treatment 111, 27-44, 2008 | 456 | 2008 |
| Differential sensitivity of liposarcoma subtypes to chemotherapy RL Jones, C Fisher, O Al-Muderis, IR Judson European journal of cancer 41 (18), 2853-2860, 2005 | 426 | 2005 |
| An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma PAtients EuroNet (SPAEN) and European organization for … B Kasper, C Baumgarten, J Garcia, S Bonvalot, R Haas, F Haller, ... Annals of Oncology 28 (10), 2399-2408, 2017 | 415 | 2017 |
| The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients B Alman, S Attia, C Baumgarten, C Benson, JY Blay, S Bonvalot, ... European Journal of Cancer 127, 96-107, 2020 | 400 | 2020 |
| Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, ... Annals of oncology 33 (1), 20-33, 2022 | 379 | 2022 |
| Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial JY Blay, C Serrano, MC Heinrich, J Zalcberg, S Bauer, H Gelderblom, ... The Lancet Oncology 21 (7), 923-934, 2020 | 376 | 2020 |
Jean-yves BlayProfesseur de Cancérologie Centre Leon Berard & University Claude Bernard Lyon IBestätigte E-Mail-Adresse bei lyon.unicancer.fr
